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ABSTRACT  
Backgrounds: Over recent years there have been some conflicting reports upon the role 
of pallidal dopaminergic denervation in rest tremor in Parkinson's disease.  
Objectives: To clarify this issue we analyzed the clinical and 123I-FP-CIT SPECT data 
of a large cohort of early Parkinson's disease patients enrolled in the PPMI study. 
Methods: Pallidal and striatal dopamine transporter uptake ratios were calculated in 
382 patients (120 no-tremor, 60 tremor-dominant, and 202 indeterminate) and 150 
controls. A region of interest (ROI) approach was used to estimate DAT uptake ratios 
from 123I-FP-CIT SPECT scans in the caudate nucleus, putamen, and globus pallidus 
after normalization to a DAT template. DAT uptake ratios for each region were 
compared between subgroups using ANCOVA and linear regression analyses were 
performed to evaluate the relationship between severity of rest tremor and regional DAT 
uptake ratios. 
Results: PD patients had significantly lower DAT uptake ratios in the pallidum, 
putamen and caudate as compared to healthy controls (p <0.001). ANCOVA showed 
inter-PD subgroup differences in DAT uptake ratios in the putamen and pallidum (p 
<0.05) after adjustment for age and disease duration, with post-hoc comparisons 
revealing significantly higher DAT uptake ratios for the tremor-dominant subgroup as 
compared to non-tremor and indeterminate subgroups (p <0.016). There was no 
significant relationship between rest tremor severity and pallidal DAT either in the 
tremor-dominant subgroup or in the total PD population. 
Conclusions: Pallidal dopaminergic denervation appears unrelated to rest tremor 
severity in early Parkinson's disease. 
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INTRODUCTION 
The pathophysiology of rest tremor in Parkinson’s disease (PD) has not been completely 
understood and several hypotheses are still in debate. Dopaminergic denervation in the 
basal ganglia is considered to be a prerequisite condition but likely constitutes only part 
of the explanation.[1] This is highlighted by several imaging studies reporting no 
correlation between striatal denervation and severity of resting tremor in PD.[2-5]  
The recently proposed ‘dimmer-switch model’[6] provides a possible explanation for 
the complex action of dopamine on rest tremor through an interplay between 
dopaminergic denervation of the globus pallidus (GP), which can be thought of as the 
trigger, and the activity of cerebello-thalamo-cortical circuit, which is responsible for 
modulating tremor severity and amplitude.[5] Critically, this model assumes that 
pallidal dopaminergic denervation be more pronounced in tremor-dominant than in 
akinesia/rigidity-dominant patients. However, whether such dopaminergic denervation 
is associated with rest tremor in PD is still controversial. While one study demonstrated 
a correlation between GP dopamine transporter (DAT) reduction and rest tremor[5], 
another study found no difference in pallidal DAT loss between patients with bilateral, 
unilateral, or without tremor.[7] It should be noted that these studies only included a 
small number of patients without controlling dopaminergic medication effect, thus 
limiting conclusiveness.  
The current study aims to investigate whether pallidal dopaminergic denervation is 
related to resting tremor severity in a large prospective cohort of early untreated PD 
patients.     
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METHODS 
Study design and participants 
PD patients and healthy controls (HC) who enrolled in the Parkinson’s Progression 
Marker Initiative (PPMI) study and received screening 123I-FP-CIT SPECT were 
eligible. PD patients were within 2 years of diagnosis and in anti-parkinsonian drug-
naïve state at the time of scanning. Reconstructed and attenuation corrected 123I-FP-CIT 
SPECT images were downloaded for 430 PD and 193 HC on 8th September 2016 from 
the PPMI database (http://www.ppmi-info.org/data). Clinical data described below were 
also downloaded on the same date.    
 
Patient Classification 
Clinical information including demographics, medication history, duration of PD, and 
scores for the Movement Disorders Society revised Unified PD Rating Scale (MDS-
UPDRS) assessed at baseline were acquired from the PPMI database. Rest tremor 
severity index was calculated based on the MDS-UPDRS part-III, defined as the 
product of the total rest tremor amplitude score (item 3.17) in the most affected side and 
constancy score (item 3.18). PD patients were classified into three subgroups; tremor-
dominant, no-tremor and indeterminate. Tremor-dominant was defined if patients had a 
rest tremor severity index ≥2; rigidity score ≤1 (item 3.3); body bradykinesia score ≤1 
(item 3.14). No-tremor was defined if patients had a rest tremor severity index score of 
zero. All other patients were classified as indeterminate.  
 
123I-FP-CIT SPECT data analysis 
Image pre-processing 
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123I-FP-CIT SPECT was performed during screening visits using standardized imaging 
protocols (http://www.ppmi-info.org/data). Downloaded 123I-FP-CIT SPECT images 
were first rigid registered to an in-house custom DAT template created from a series of 
thirty-three 11C-PE2I positron emission tomography scans,[8] which is a radioligand 
with high specificity for DAT.[9, 10] Registered 123I-FP-CIT images were then spatially 
normalized to this DAT template using 12-parameter affine registration and non-linear 
warping procedure in SPM12 (Statistical Parametric Mapping, Wellcome Trust Centre 
for Neuroimaging, London, UK). A T1-weighted anatomical template in spatial 
correspondence with the DAT template[8] was then used for manual ROI delineation. 
We opted for this procedure to ensure anatomically accurate and consistent delineation 
with particular regard for discrimination within the lentiform nucleus and to reduce 
potential operator bias otherwise inherent in regional tracing based on SPECT voxel 
intensities. All normalized SPECT images were visually inspected against DAT and T1-
weighted templates to ensure adequate alignment.  
 
Region of interest analysis 
Regions of interest (ROI) were manually drawn for the bilateral putamen, caudate 
nucleus, GP and occipital cortex on the T1-weighted template in Analyze 11.0 
(Biomedical Imaging Resource, Mayo Clinic, Rochester, MN). Hemispheric ROI 
volumes for the putamen, caudate, and GP were 3592mm3, 2760mm3 and 1624mm3, 
respectively. The occipital cortex was used as a reference region and defined by placing 
a circular ROI in each hemisphere on 10 sequential slices (ROI volume =5920mm3) 
(Supplementary figure). The specific DAT binding ratio for each ROI was calculated as 
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in our previous paper:[11] Specific binding ratio= 
ROI counts
pixels -
occipital counts
pixels 
occipital countspixels 
  
 
 
Statistical analysis 
Statistical analyses were performed using IBM SPSS version 22 (Armonk, NY: IBM 
Corp). Differences in baseline clinical/demographic characteristics between PD 
subgroups were assessed using one-way analysis of variance (ANOVA) for continuous 
variables, Kruskal-Wallis test in cases where normality (Shapiro-Wilk <0.05) was 
violated and for binary variables using chi-square test. Group comparison of regional 
DAT uptake ratios averaged across hemispheres between PDAll and HC groups was 
conducted using independent t-tests. One-way analysis of covariance (ANCOVA), 
adjusting for age and followed by post-hoc Bonferroni comparisons was utilized to 
evaluate differences in DAT uptake ratios between PD subgroups for the more and less 
affected hemispheres separately. Associations between rest tremor (rest tremor severity 
index, tremor amplitude, constancy of tremor) and pallidal and putaminal DAT uptake 
ratios were investigated using linear regression with age as a nuisance covariate.  
 
 
RESULTS 
Subjects were excluded due to unavailable clinical data (23 PD, 35 HC) and poor image 
acquisition or failure in normalization (25 PD, 8 HC). 382 PD [PDAll: 134 females 
(35.1%), age =61.8 ±9.5 years] and 150 HC [51 females (34%), age =61.2 ±11.0 years] 
participants were therefore included in the final analysis. There were no significant 
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differences in age and sex distributions between PDAll and HC groups. Sixty patients 
were classified as tremor-dominant, 120 patients as no-tremor and 202 patients as 
indeterminate. Clinical comparisons between the three PD subgroups are shown in 
Table 1. Compared with no-tremor and indeterminate, the tremor-dominant subgroup 
had milder disease, showing significantly lower MDS-UPDRS scores and HY stage. 
Rest tremor severity index was highest in the tremor-dominant subgroup (Table 1).  
 
Dopamine transporter uptake ratios  
PDAll group had significantly reduced DAT uptake ratios compared to HC in all three 
ROIs (p <0.001). Mean reductions in DAT uptake ratios for the PDAll group were 28.2% 
for caudate nucleus, 38.9% for putamen and 43.1% for GP.  
When we compared DAT uptake ratios amongst PD subgroups, significant inter-
subgroup differences were found in both sides of the putamen and in the less affected 
GP (Supplementary table). Post-hoc analysis revealed that the tremor-dominant 
subgroup had higher DAT uptake ratios in the putamen compared to the indeterminate 
subgroup, and in the less affected GP as compared to the no-tremor subgroup (Figure 1). 
No significant results were found for caudate DAT uptake ratios. 
 
Linear regression analysis  
No significant relationship was found between GP DAT uptake ratios and rest tremor 
severity index, tremor amplitude or constancy of rest tremor scores in the tremor-
dominant PD subgroup as well as in the PDAll group (p >0.05). This lack of association 
was consistently shown in both the more affected and less affected GP (p >0.05). 
Additionally, we found no significant relationship between putaminal DAT uptake ratios 
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and tremor severity measures in both tremor-dominant and PDAll groups (p >0.05).  
 
 
DISCUSSION 
In a large cohort of early PD patients, we found that tremor-dominant patients exhibit 
milder putaminal and pallidal dopaminergic denervation compared with indeterminate 
and no-tremor PD cases, despite differences in disease duration. Additionally, pallidal 
DAT availability was not predictive of rest tremor severity in this cohort. 
Our findings are in agreement with those previously reported by Isaias and colleagues[7] 
and therefore do not support the interpretation that tremor severity is associated with 
more severe dopamine depletion in the pallidum, as proposed by Helmich and 
colleagues.[5] However, SPECT used in all these studies including ours has limited 
resolution for GP, so we tried to enhance accuracy and consistency in regional 
delineation by using corresponding DAT and T1-weighted anatomical templates in our 
imaging analysis pipeline, and analyzed data from a significantly large number of drug-
naïve PD patients, therefore our measures were both unaffected by drug treatment and 
more robust than in previous reports. In line with our in vivo observations, one post-
mortem biochemical study in eight PD and five control brains showed that dopamine 
loss was less severe in tremor-dominant cases compared to akinetic-rigid and classic PD 
types in the GP, as well as in the putamen.[12] In the present study, we clearly 
demonstrate a milder degree of pallidal dopaminergic denervation in tremor-dominant 
PD patients.  
Our results however, are not necessarily in opposition to those indicating a close 
relationship between pallidal activity and rest tremor[5, 6] as they only reflect early 
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disease and tremor mechanisms may change with PD progression. It is possible that GP 
dysfunction may become worse over time and contribute to tremor as described by 
Helmich and colleagues in patients at more advanced stages than ours.[5] The 
underlying mechanism may just be more complex and probably involve dopaminergic 
and non-dopaminergic input rather than dopaminergic input alone. In the PPMI cohort, 
we have previously reported reductions of serotonin transporter availability in the raphe 
nuclei that correlated with measures of rest tremor severity.[11] Noradrenergic 
involvement has also been suggested, though further larger scale work is required to 
confirm this[7].       
In conclusion, we have demonstrated a limited role of pallidal dopaminergic 
denervation in early parkinsonian rest tremor. We suggest that non-dopaminergic 
mechanisms may be of importance for the clinical feature of rest tremor in PD.  
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Figure Legends 
Figure 1. Comparisons of dopamine transporter uptakes in the pallidum, putamen, 
and caudate nucleus between the Parkinson’s disease subgroups. A. DAT uptakes in 
the more affected hemisphere. B. DAT uptakes in the less affected hemisphere. DAT 
uptakes in healthy controls are plotted as a reference showing averaged values of both 
hemispheres. ANCOVA test results adjusting for age are presented above respective 
plots. In the post-hoc analysis, the tremor-dominant subgroup had higher DAT uptakes 
in the less affected pallidum compared with the no-tremor subgroup (p =0.010, age & 
PD duration-adjusted), and in both more and less affected putamen compared to the 
indeterminate subgroup [p =0.011 (A) and 0.010 (B), age & PD duration-adjusted]. 
DAT =dopamine transporters, HC =healthy controls, *Denotes significant pairwise 
comparison at p <0.016. 
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Table 1. Baseline characteristics of the tremor-dominant, no-tremor and 
indeterminate PD subgroups  
 
Supplementary Table. Comparison of DAT uptake ratios between the three PD 
subgroups.  
 
Supplementary Figure. A representative picture of ROI placement on the normalized 
SPECT image. ROIs were manually drawn using the Analyze 11.0 (Biomedical Imaging 
Resource, Mayo Clinic, Rochester, MN) on the T1-weighted anatomical template in 
spatial correspondence with the DAT template. 
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Table 1. Baseline characteristics of the tremor-dominant, no-tremor and 
indeterminate PD subgroups  
Characteristics 
Indeterminate 
(n =202) 
No-tremor 
(n =120) 
Tremor-dominant 
(n =60) 
p-value 
Gender, female, n (%) 75 (37.1) 36 (30.0) 23 (38.3) 0.366* 
Age, years 62.8 ±9.0 59.1 ±9.7 63.7 ±9.6 0.001ac 
Duration of PD, months 7.7 ±7.6 4.8 ±4.0 6.1 ±5.8 <0.001c 
MDS-UPDRS total score 34.7 ±12.7 31.2 ±13.0 24.0 ±8.8 <0.001abc 
   Part 1 1.2 ±1.6 1.4 ±1.6 1.0 ±1.3 0.226 
   Part 1 - questionnaires 4.5 ±3.0 4.3 ±3.2 3.9 ±3.7 0.514 
   Part 2 6.1 ±4.3 6.4 ±4.4 4.5 ±3.1 0.010ab 
   Part 3 22.8 ±8.7 19.1 ±8.2 14.6 ±4.3 <0.001abc 
Hoehn & Yahr stage 1.6 ±0.5 1.6 ±0.5 1.4 ±0.5 <0.001ab† 
Rest tremor severity index 3.72 ±3.38 0 5.10 ±3.10 <0.001abc 
Amplitude of rest tremor 1.72 ±0.97 0.04 ±0.21 2.13 ±0.79 <0.001abc 
Consistency of rest tremor 1.86 ±1.00 0.04 ±0.20 2.35 ±0.97 <0.001abc 
Data are shown as mean ±standard deviation unless otherwise indicated. 
PD =Parkinson’s disease; MDS-UPDRS =Movement Disorders Society Task Force revised Unified 
Parkinson’s disease rating scale. Bold style means statistical significance. Comparison was done using the 
ANOVA test with post-hoc analysis unless otherwise specified.  
*comparison by the Chi-square test 
†comparison by the Kruskall-Wallis test 
asignificant difference between the tremor-dominant vs. no-tremor subgroups, corrected p <0.05 
bsignificant difference between the tremor-dominant vs. indeterminate subgroups, corrected p <0.05 
csignificant difference between the no-tremor vs. indeterminate subgroups, corrected p <0.05 
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Highlights 
Tremor-dominant PD patients had relatively mild dopaminergic denervation. 
Pallidal DAT density could not determine rest tremor severity in drug-naïve PD. 
Nondopaminergic mechanism in the pallidum might be important for rest tremor in PD. 
 
